Atricure announces the first patient treated in the boxx-noaf clinical trial

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced that the first patient was enrolled and treated in the box lesion creation with left atrial appendage exclusion to reduce the occurrence of new-onset atrial fibrillation (boxx-noaf) clinical trial (nct06989775). the first patient was treated by dr. anthony r.
ATRC Ratings Summary
ATRC Quant Ranking